Regina Jones Senior Vice President General Counsel and Secretary | ADM
ADM, a global company known for its natural solutions, has announced an exclusive agreement with Asahi Group Foods Corporation. This collaboration will see ADM market and distribute Asahi Group's postbiotic product, Lactobacillus gasseri CP2305, which is designed to aid stress, mood, and sleep. The postbiotic is supported by eight human clinical trials.
Mark Lotsch, President of Global Health & Wellness at ADM, commented on the partnership: "Stress, mood and sleep are among the fastest-growing wellness segments, and – as the cornerstone to physical and emotional health – they are also some of the most disruptive factors to everyday life and overall well-being if not properly supported." He added that this agreement with Asahi Group represents a significant step in enhancing their health and wellness offerings.
Lactobacillus gasseri CP2305 was developed after extensive research into Calpis-derived lactic acid bacteria. The partnership allows Asahi Group to leverage ADM's expansive network to meet rising demand for functional food products globally. Kazuhiro Hayashi from Asahi Group expressed enthusiasm about the agreement: "Asahi is committed to solving global food and health challenges... We're excited to enter a supply agreement with ADM for Lactobacillus gasseri CP2305."
The postbiotic offers potential benefits such as improved emotional well-being, better sleep efficiency, reduced stress levels, and enhanced overall sleep quality. Its resilience makes it suitable for various formulation environments common in functional foods.
ADM has previously published studies highlighting other probiotics' health benefits. These include Bifidobacterium longum CECT 7347 (ES1) for gut health and BPL1** (Bifidobacterium animalis subsp. lactis CECT 8145) for metabolic health support.